Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some. - Wikidata - wikimedia - TriplyDB

Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some.

Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some.

http://www.wikidata.org/entity/Q38413904

about

Epigenetic mechanisms involved in melanoma pathogenesis and chemoresistance Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling Monoclonal antibodies: Principles and applications of immmunodiagnosis and immunotherapy for hepatitis C virus Mesenchymal Stromal Cells Can Regulate the Immune Response in the Tumor Microenvironment Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette-Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma CD176 single-chain variable antibody fragment inhibits the adhesion of cancer cells to endothelial cells and hepatocytes.Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets.Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes.Chemo-immunotherapy induces tumor regression in a mouse model of spontaneous mammary carcinogenesis.Gold nanoparticles and vaccine development.Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies.The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab Editorial: "Cancer Immunotherapy: Lights and Shadows".Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma.Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma Unique Immune Gene Expression Patterns in Bronchoalveolar Lavage and Tumor Adjacent Non-Neoplastic Lung Tissue in Non-Small Cell Lung Cancer.How to Hit Mesenchymal Stromal Cells and Make the Tumor Microenvironment Immunostimulant Rather Than Immunosuppressive.Differential role of CXCR3 in inflammation and colorectal cancer.High Densities of Tumor-Associated Plasma Cells Predict Improved Prognosis in Triple Negative Breast Cancer.Ultrasound-mediated microbubble destruction: a new method in cancer immunotherapy

P2860

Q26778761-93C8875E-BBA4-4877-837F-0FDDA4915445 Q26781643-18A47F0A-8056-4CF9-B16C-79313BA28210 Q26783378-50B9B2A7-28AC-42CC-8D7B-F209D79CAF92 Q28073613-BA09BAF0-5791-4B3C-8ABB-0F87FECF6387 Q33741471-88CF2DD6-F27E-44B5-B9C2-7BD2B4E4F033 Q35993085-4EFC7E79-1438-4967-A571-34290F6BABFD Q36050577-0DF3A677-54A9-4DDF-B6D6-F3252D14158C Q36586109-B3A6B4B9-C6F2-4814-9A21-7C4C22DAB015 Q37644937-9371349D-936A-429E-A844-1E7D6AAAD7D6 Q38543673-16FCD777-270C-4A03-B01C-1C90BDE528DC Q38670099-10E25010-0CF4-4D1E-A1B8-92694F0FA5A3 Q38831232-B6AF293C-07FB-45DC-9557-E366386ECDCC Q41048538-AF8198EB-2453-4C76-8AB4-BEE6C4EC380C Q41326480-92A215E6-CEFC-411A-929B-A42B52355911 Q42327769-4F0F75CF-D74D-4571-90BA-63AF11AFA530 Q42362520-40003344-0B2C-4A47-8F61-7A533D4BE2B5 Q50300234-10C8C211-80FF-4185-AB40-0952135F9F6F Q52668325-1B6E5D3F-3CF5-4EF2-AD13-361524A00E85 Q55131902-D5CDDAD2-331C-4AE7-A1AB-B40060BFC573 Q55345031-E7565F44-F2B6-4FF4-9B63-49855EBC0B2E Q58746739-73487087-BC7C-4440-9DF9-6965A82EC7B8

P2860

Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some.

http://www.wikidata.org/entity/Q38413904

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Immunotherapy in Cancer: A Com ...... ; You Win Some, You Lose Some.

@en

type

label

Immunotherapy in Cancer: A Com ...... ; You Win Some, You Lose Some.

@en

prefLabel

Immunotherapy in Cancer: A Com ...... ; You Win Some, You Lose Some.

@en

P1433

Q38413904-82D607DF-2BB9-4811-85DA-BBCD7FD2640B

P1476

Q38413904-18AB8129-EFA3-47AF-8BA1-97B13810B684

P2093

Q38413904-09467961-45D8-4DE0-ADF5-0DA7812E2D01

Q38413904-266C9F2F-B226-46F0-AE6A-472C6291FA8F

Q38413904-26CFFA87-BE66-400D-B48F-E3FE1ED479D7

Q38413904-AEA07DCD-F19F-4ADF-BFFB-025F6CCE3776

P2860

Q38413904-00906087-4617-41C5-8ED5-C4F4C9BD7B00

Q38413904-01379EEE-CBAD-4AAB-8BD8-F90B8C56F9B8

Q38413904-02388F95-9F3D-4497-88C1-E2A98C7363D9

Q38413904-0831F70B-A08E-43E2-B63A-761012DF0E68

Q38413904-0BD6E0A5-921C-4D8D-8E93-03F9DD8E84F6

Q38413904-0C091BBD-4349-48EB-9549-4414BC4B992D

Q38413904-0E8A6FF3-854D-4994-95CB-4DD97CA2CE92

Q38413904-0FB3A2E1-DCB8-43BE-92AD-4F984156A8E7

Q38413904-11495D9E-9BA9-4D06-A3C9-F1642BCB93BC

Q38413904-11CAAC6E-3766-43A1-AD48-E57894C3AD45

P304

Q38413904-0BAC1AB1-E159-4697-84F7-1F263CF18A26

P31

Q38413904-9A708A18-C7DA-434E-8347-3E46AF2D21C5

P356

Q38413904-D039D470-60A4-4D2B-99B2-377F6CDBABCC

P478

Q38413904-F98F1270-586F-40AC-8F8C-4AC0D92D5CA6

P50

Q38413904-2298610F-86BA-4C76-8926-F1D85ADE3979

P577

Q38413904-60148E96-0DE2-4DD1-9AE7-69179D6B2D0D

P5875

Q38413904-15535588-5296-454E-98F9-BD55CB206700

P698

Q38413904-3DD82489-AB32-44DC-BBD9-AE161F9C277D

P932

Q38413904-1150EB3C-1404-4B79-BEF9-15A5BA5216F8

P356

FIMMU.2015.00127

P1433

Frontiers in Immunology

P1476

Immunotherapy in Cancer: A Com ...... ; You Win Some, You Lose Some.

@en

P2093

Antonela Baron

http://www.w3.org/2001/XMLSchema#string

Florencia Paula Madorsky Rowdo

http://www.w3.org/2001/XMLSchema#string

José Mordoh

http://www.w3.org/2001/XMLSchema#string

Mariela Urrutia

http://www.w3.org/2001/XMLSchema#string

P2860

Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production

Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.

Complement activation selectively potentiates the pathogenicity of the IgG2b and IgG3 isotypes of a high affinity anti-erythrocyte autoantibody

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

P304

127

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FIMMU.2015.00127

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Mariela Urrutia

P577

2015-03-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

274722793

http://www.w3.org/2001/XMLSchema#string

P698

25859247

http://www.w3.org/2001/XMLSchema#string

P932

4374472

http://www.w3.org/2001/XMLSchema#string